Assessing the Safety and Tolerability of NMN in DHDDS-CDG

NCT07572825 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

8

Enrollment

OTHER

Sponsor class

Conditions

DHDDS-Congenital Disorder of Glycosylation
DHDDS-CDG
Congenital Disorder of Glycosylation

Interventions

DRUG: Nicotinamide Mononucleotide (NMN) Nucleosidase

Sponsor

Eva Morava-Kozicz